Regulation of the IL-10/IL-12 axis in human dendritic cells with probiotic bacteria

FEMS Immunology and Medical Microbiology

Volumn 63, Issue 1, 2011, Pages 93-107

  Gad, Monika ^a   Ravn, Peter ^a   Søborg, Ditte A ^a   Lund Jensen, Karina ^a   Ouwehand, Arthur C ^b   Jensen, Simon S ^a  

^a BIONEER A S   (Denmark)

^b Danisco Finland Oy   (Finland)

Author keywords

Anti inflammatory; Commensal bacteria; Dendritic cells; IL 12; Immune modulation; Probiotics

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 23; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DOSE RESPONSE; ESCHERICHIA COLI; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS PLANTARUM; LACTOBACILLUS SALIVARIUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SACCHAROMYCES BOULARDII; SCREENING; STREPTOCOCCUS SALIVARIUS; STREPTOCOCCUS THERMOPHILUS; TH1 CELL;

BACTERIA; CELLS, CULTURED; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; PROBIOTICS; SACCHAROMYCES;

EID: 80052604385     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2011.00835.x     Document Type: Article

References (44)

1. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C & Sartor RB (2005) VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol100: 1539-1546.
2. Borruel N, Carol M, Casellas F, Antolín M, de Lara F, Espín E, Naval J, Guarner F & Malagelada JR (2002) Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut51: 659-664.
3. Bouma G & Strober W (2003) The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol3: 521-533.
4. Cella M, Döhring C, Samaridis J, Dessing M, Brockhaus M, Lanzavecchia A & Colonna M (1997) A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med185: 1743-1751.
5. Christensen HR, Frøkiaer H & Pestka JJ (2002) Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol168: 171-178.
6. Coombes JL & Powrie F (2008) Dendritic cells in intestinal immune regulation. Nat Rev Immunol8: 435-446.
7. Drakes M, Blanchard T & Czinn S (2004) Bacterial probiotic modulation of dendritic cells. Infect Immun72: 3299-3309.
8. Foligne B, Nutten S, Grangette C, Dennin V, Goudercourt D, Poiret S, Dewulf J, Brassart D, Mercenier A & Pot B (2007a) Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroentero13: 236-243.
9. Foligne B, Zoumpopoulou G & Dewulf J (2007b) A key role of dendritic cells in probiotic functionality. PLoS One2: e313.
10. Fuss IJ, Becker C, Yang Z, Groden C, Hornung RL, Heller F, Neurath MF, Strober W & Mannon PJ (2006) Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis12: 9-15.
11. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M & Campieri M (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124: 1202-1209.
12. Goriely S, Neurath MF & Goldman M (2008) How microorganisms tip the balance between interleukin-12 family members. Nat Rev Immunol8: 81-86.
13. Guslandi M, Mezzi G, Sorghi M & Testoni PA (2000) Saccharomyces boulardii in maintenance treatment of Crohn's disease. Digest Dis Sci45: 1462-1464.
14. Guslandi M, Giollo P & Testoni PA (2003) A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroen Hepat15: 697-698.
15. Hart AL, Lammers K, Brigidi Pet al. (2004) Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut53: 1602-1609.
16. Jensen SJ & Gad M (2010) Differential induction of inflammatory cytokines by dendritic cells treated with novel TLR-agonist and cytokine based cocktail: targeting dendritic cells in autoimmunity. J Inflamm 7: 37.
17. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM & Zinsmeister AR (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharm Therap17: 895-904.
18. Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G & Zinsmeister AR (2005) A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroent Motil17: 687-696.
19. Kobayashi T, Okamoto S, Hisamatsu Tet al. (2008) IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohns disease. Gut57: 1682-1689.
20. Konstantinov SR, Smidt H, de Vos WM, Bruijns SC, Singh SK, Valence F, Molle D, Lortal S, Altermann E & Klaenhammer TR (2008) S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. P Natl Acad Sci USA105: 19474-19479.
21. Kruis W, Fric P, Pokrotnieks Jet al. (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut53: 1617-1623.
22. Malchow HA (1997) Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?J Clin Gastroenterol25: 653-658.
23. Maupas JL, Champemont P & Delforge M (1983) Treatment of irritable bowel syndrome. Double blind trial of Saccharomyces boulardii. Médecine Chirurgie Digestives2: 77-79.
24. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M & Kamm MA (2004) Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut53: 108-114.
25. Neurath MF (2007) IL-23: a master regulator in Crohn disease. Nat Med 13: 26-28.
26. Öhman L, Isaksson S, Lindmark AC, Posserud I, Stotzer PO, Strid H, Sjövall H & Simrén M (2009) T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol104: 1205-1212.
27. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK & Shanahan F (2005) Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128: 541-551.
28. Paineau D, Carcano D, Leyer G, Darquy S, Alyanakian MA, Simoneau G, Bergmann JF, Brassart D, Bornet F & Ouwehand AC (2008) Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunol Med Mic 53: 107-113.
29. Pamer EG (2007) Immune responses to commensal and environmental microbes. Nat Immunol11: 1173-1178.
30. Plassmann D & Schulte-Witte H (2007) Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN): a retrospective survey. Med Klin 102: 888-892.
31. Pothoulakis C, Kelly CP, Joshi MA, Gao N, O'Keane CJ, Castagliuolo I & Lamont JT (1993) Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology104: 1108-1115.
32. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM & Axon AT (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354: 635-639.
33. Round JL & Mazmanian SK (2009) The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol9: 313-323.
34. Shortman K & Naik SH (2007) Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol7: 19-30.
35. Sokol H, Pigneur B, Watterlot Let al. (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. P Natl Acad Sci USA105: 16731-16736.
36. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W & Remaut E (2000) Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science289: 1352-1355.
37. Tasteyre A, Barc MC, Karjalainen T, Bourlioux P & Collignon A (2002) Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microb Pathogenesis5: 219-225.
38. Thomas S, Przesdzing I, Metzke D, Schmitz J, Radbruch A & Baumgart DC (2009) Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. Clin Exp Immunol156: 78-87.
39. Tursi A (2004) Acute diverticulitis of the colon - current medical therapeutic management. Expert Opin Pharmaco5: 55-59.
40. Vanderpool C, Yan F & Polk DB (2008) Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis 14: 1585-1596.
41. Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH & Noelle RJ (2008) Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+regulatory T cells. P Natl Acad Sci USA105: 9331-9336.
42. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F & Quigley EM (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol101: 1581-1590.
43. Zeuthen LH, Christensen HR & Frøkiaer H (2006) Lactic acid bacteria inducing a weak interleukin-12 and tumor necrosis factor alpha response in human dendritic cells inhibit strongly stimulating lactic acid bacteria but act synergistically with gram-negative bacteria. Clin Vaccine Immunol13: 365-375.
44. Zhang Y, Chung Y, Bishop Cet al. (2006) Regulation of T cell activation and tolerance by PDL2. P Natl Acad Sci USA103: 11695-11700.